WO2002096429A1 - Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant - Google Patents
Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant Download PDFInfo
- Publication number
- WO2002096429A1 WO2002096429A1 PCT/RU2002/000267 RU0200267W WO02096429A1 WO 2002096429 A1 WO2002096429 A1 WO 2002096429A1 RU 0200267 W RU0200267 W RU 0200267W WO 02096429 A1 WO02096429 A1 WO 02096429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- per
- finished product
- medium
- amount
- psoriasis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- the invention is only for external use and may be used for external therapy.
- the methods of treating the disease with the use of physical exposure to the affected skin are known.
- ⁇ a ⁇ , na ⁇ ime ⁇ , izves ⁇ en s ⁇ s ⁇ b treatment dissemini ⁇ vann ⁇ g ⁇ ⁇ s ⁇ iaza, v ⁇ lyuchayuschy se ⁇ al- hydrochloric ⁇ i ⁇ des ⁇ u ⁇ tsiyu ⁇ chag ⁇ v ⁇ azhen ⁇ 4ya ⁇ zhi, s ⁇ glasn ⁇ ⁇ mu ⁇ e ⁇ ed ⁇ i ⁇ des ⁇ u ⁇ tsiey ⁇ izv ⁇ dya ⁇ ⁇ b ⁇ ab ⁇ u ⁇ i ⁇ e ⁇ m and ⁇ i ⁇ v ⁇ zdeys ⁇ - Wier che ⁇ eduyu ⁇ with gem ⁇ s ⁇ btsiey ( ⁇ , 2036667).
- Access to this equipment is a complication of implementation, due to the need to use special equipment.
- physiological oil at a temperature of 50-60 ° C and the target product
- exudative disease The means of medication for the treatment of a disease are known.
- Alkylglycerol ( ⁇ ⁇ , 1837877).
- the raw materials are sold by the consumer and the consumables are in accordance with the quality of the raw materials used by the manufacturer, and the
- the extraction is carried out by the processor, the extract is evaporated, and the calculation is taken by the extraction of lipids from the oxygen concentrate of 15
- the cost of this method is the complexity of implementation.
- the means for external therapy of a disease including active and fertile substances, are subject to
- the equipment may optionally be equipped with ⁇ 2 - accessories,
- piropoxane in the amount of 0.005 - 0.18 g per 1 g of finished product or sugar in the amount of 0.012 - 0.12 g per 1 g of finished product in the amount of 0.012 - 0.12 g per 1 g of finished product
- varieties in amounts of 0.002–0.012 g per 1 g of finished product or salbutamum in amounts of 0.002–0.012 g per 1 g of finished product are examples.
- the improved liposomal emulsion adds a fat base
- a ready-made product in the form of an aroma is obtained.
- Declared medium may be sold using
- the food supplement “Lecithin” mixed with a cleaner at a ratio of 1: 1 in case of deterioration is spilled into the flask.
- its residues (steams) are removed by blowing the flask with nitrogen.
- a flask containing the declared active substances is introduced into the flask. Then, for a period of time, continuous stirring of the continuous flask is carried out at a temperature of 36 -
- the treatment of the disease was carried out by the plant.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention vise une nouvelle forme de médicament destinée au traitement du psoriasis de l'extérieur aux stades aigus de cette maladie. Le produit destiné au traitement du psoriasis de l'extérieur est caractérisé en ce que l'on utilise en tant que substances actives des préparations du groupe des méthylxanthines, des préparations de sélénium et quelques additifs; en tant que composés supplémentaires on utilise une base lipidique, de l'huile végétale raffinée et de l'eau. L'additif alimentaire 'Lécithine', mélangé à du cholestérol dans des proportions 1 à 1 par rapport à la phosphatidylcholine, est dissout dans le chloroforme. Après l'évaporation du chloroforme on injecte dans la fiole une solution contenant les substances actives de l'invention. On procède ensuite au mélangeage du contenu de la fiole à une température entre 36 et 40 °C, ce qui permet d'obtenir une émulsion liposomale qui, additionnée d'une base lipidique (lanoline) et d'une huile végétale (p.ex., huile d'olives), forme après le mélangeage un produit prêt se présentant comme une crème ayant la consistance voulue. Le produit de l'invention se distingue avantageusement de tous les produits connus par le succès de son utilisation aux stades aigus de la maladie, lorsque d'autres produits tels que le goudron et l'anthraline sont contre-indiqués, ainsi qu'en cas de psoriasis exsudatif et de psoriasis du cuir chevelu, lorsque les produits connus se montrent inefficaces.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2001114783 | 2001-05-29 | ||
RU2001114783/14A RU2196583C1 (ru) | 2001-05-29 | 2001-05-29 | Средство для наружной терапии псориаза и способ его изготовления |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002096429A1 true WO2002096429A1 (fr) | 2002-12-05 |
Family
ID=20250213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2002/000267 WO2002096429A1 (fr) | 2001-05-29 | 2002-05-23 | Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2196583C1 (fr) |
WO (1) | WO2002096429A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2456976C1 (ru) * | 2010-12-27 | 2012-07-27 | Роман Арикович Грашин | Лекарственная композиция для лечения заболеваний кожи (варианты) |
RU2724049C1 (ru) * | 2019-04-11 | 2020-06-19 | Роман Арикович Грашин | Средство для наружной терапии наиболее часто встречающихся дерматозов |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061753A (en) * | 1976-02-06 | 1977-12-06 | Interx Research Corporation | Treating psoriasis with transient pro-drug forms of xanthine derivatives |
US5565462A (en) * | 1991-09-02 | 1996-10-15 | Teva Pharmaceutical Industries, Ltd. | Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative |
RU2125443C1 (ru) * | 1993-12-30 | 1999-01-27 | Л'Ореаль | Косметическая или дерматологическая композиция для одновременного лечения поверхностных и глубоких слоев кожи и ее применение |
RU2152218C1 (ru) * | 1998-04-21 | 2000-07-10 | Дальневосточный государственный медицинский университет | Способ лечения псориаза |
RU2163486C1 (ru) * | 2000-03-28 | 2001-02-27 | Щиголева Светлана Александровна | Средство для лечения псориаза, витилиго и алопеции |
-
2001
- 2001-05-29 RU RU2001114783/14A patent/RU2196583C1/ru active IP Right Revival
-
2002
- 2002-05-23 WO PCT/RU2002/000267 patent/WO2002096429A1/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061753A (en) * | 1976-02-06 | 1977-12-06 | Interx Research Corporation | Treating psoriasis with transient pro-drug forms of xanthine derivatives |
US5565462A (en) * | 1991-09-02 | 1996-10-15 | Teva Pharmaceutical Industries, Ltd. | Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative |
RU2125443C1 (ru) * | 1993-12-30 | 1999-01-27 | Л'Ореаль | Косметическая или дерматологическая композиция для одновременного лечения поверхностных и глубоких слоев кожи и ее применение |
RU2152218C1 (ru) * | 1998-04-21 | 2000-07-10 | Дальневосточный государственный медицинский университет | Способ лечения псориаза |
RU2163486C1 (ru) * | 2000-03-28 | 2001-02-27 | Щиголева Светлана Александровна | Средство для лечения псориаза, витилиго и алопеции |
Also Published As
Publication number | Publication date |
---|---|
RU2196583C1 (ru) | 2003-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69930792T2 (de) | Verfahren zur Herstellung eines Propolis-Extraktes, das einenm Anionenaustauschschritt umfasst | |
KR100539495B1 (ko) | 글리코실-엘-아스코르브산의아실화유도체 | |
TWI550063B (zh) | Antioxidant composition | |
JP4002654B2 (ja) | 血中脂質改善剤、サイクリックampホスホジエステラーゼ阻害剤、及び肥満の予防・解消剤、並びに飲食品及び皮膚外用剤 | |
JP4812222B2 (ja) | ミネラル吸収促進剤 | |
JP5027361B2 (ja) | ヒアルロン酸産生促進剤 | |
WO2001049822A2 (fr) | Agents physiologiquement actifs contenant dithioglyols et leur application dans differentes secteurs | |
WO2002096429A1 (fr) | Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant | |
CN107669536A (zh) | 一种桑树茶油祛痘膏及用法食品药膏日化品理疗药膏 | |
JP4641090B2 (ja) | 高血圧症予防・治療剤 | |
JP2004137218A (ja) | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 | |
JP2004137287A (ja) | 高血圧症予防・治療剤 | |
JP2008088131A (ja) | 抗コレステロール組成物 | |
JPH0912466A (ja) | 脂質の吸収阻害・排出促進剤および高脂肪食品 | |
CN107550963A (zh) | 一种千里光消疮液及用法食品药液日化品理疗药液含护肤 | |
CN107456468A (zh) | 一种杉皮茶油袪疤痕膏及用法食品药膏日化品理疗药膏 | |
CN107412445A (zh) | 一种柏枝茶油止血膏及用法食品药膏日化品理疗药膏 | |
TW470749B (en) | Propolis extract with improved water-solubility | |
JP2002080357A (ja) | 高血圧症予防・改善・治療剤 | |
RU2127068C1 (ru) | Биоактивный препарат "доброй ночи" | |
KR20140059957A (ko) | 꾸지뽕나무 열매의 추출물을 포함하는 비만 치료 및 개선용 조성물 | |
EP0263126A1 (fr) | Compositions roborantes sous forme d'emulsion stable | |
Taylor | Herbal detox: Ease the load on your metabolism in natural ways | |
RU2199328C1 (ru) | Состав, обладающий общеукрепляющим и тонизирующим действием | |
KR20230173476A (ko) | 로열젤리 및 프로폴리스 원괴의 혼합물을 포함하는 항산화용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KP LT LV MK MX NO PL RO SG SI SK TR UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: DEEMED TO BE WITHDRAWN AS FEES WERE NOT PAID WITHIN SPECIFIED TIME LIMITS |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |